IBRN vs IHI: Holdings Overlap & Returns
Over the year to Nov 13, 2026, IBRN returned +19.8% to IHI's −7.4%; 1% of their weight is in the same names.
- Return gap
- +27.2 pts1 year to Nov 13, 2026: IBRN ahead, total return
- Fee gap
- 0.10 ptsA year: IBRN 0.47%, IHI 0.37%, per filings dated Nov 21, 2025 and Jul 27, 2026
- Overlap
- 1%Share of the two books held in common, holdings dated Nov 12, 2026
- Net flow
- +$2m / +$76mIBRN / IHI, Oct 13, 2026 to Nov 12, 2026, daily basis
Compare two other funds
Growth of 100
Drawn from the numbers on this page. Growth of 100, both funds, distributions reinvested
IBRN +19.8%, IHI −7.4%: IBRN +27.2 pts ahead, 1 year, Nov 13, 2025 to Nov 13, 2026.
ShareUse this comparison
Cost to trade
Hypothetical. A $10,000 order in IBRN costs about $16.00 one way and $32.00 in and out, at a median spread of 0.32%. The 0.32% spread is IBRN’s 30-day median, from iShares (fund page).
Fees over time
Hypothetical. $10,000 in IBRN for 10 years at 0.47% a year costs about $778 in fees and lost growth; IHI at 0.37% would cost $615. Assumes 6% a year before fees, a sample rate, not a forecast.
How each fund moved
5% of IBRN's weight is in S&P 500 companies and 95% is outside the index. Holdings as of Nov 12, 2026.
89% of IHI's weight is in S&P 500 companies and 12% is outside the index. Holdings as of Nov 12, 2026.
Key numbers
IHI costs 0.10 points a year less; their one-year returns differ by 27.2 points; IHI is far larger, $4.0bn against $8.6m.
Pair scorecard
Open the table
Points (pts) are percentage points.
| Total return, 1 year | +19.8% | −7.4% |
|---|---|---|
| Below its all-time high | 15.9%, high on Aug 19, 2026 | 11.5%, high on Sep 8, 2021 |
| What it tracks | Therapeutics and medical devices | Therapeutics and medical devices |
| Expense ratio | 0.47% | 0.37% |
| Net assets, as of Nov 12, 2026 | $8.6m | $4.0bn |
| Holdings in common | 1% |
The numbers behind it
Net assets: $8.6m on Nov 12, 2026 for iShares Neuroscience and Healthcare ETF, and $4.1bn on Nov 13, 2026 for iShares U.S. Medical Devices ETF.
Holdings in common uses holdings dated Nov 12, 2026.
What they share
By the books each fund has filed, IBRN and IHI hold 1% of their money in the same securities at the same weight. Holdings dated Nov 12, 2026.
half
1% in common
Held in common
Show all 3 holdings
| AXOGEN | 4.28% | 0.41% |
| INTEGRA LIFESCIENCES HOLDINGS | 1.05% | 0.12% |
| CERIBELL | 1.00% | 0.08% |
Only in IBRN
Show all 8 holdings
| BIOGEN | 5.33% |
| NEUROCRINE BIOSCIENCES | 5.09% |
| EDGEWISE THERAPEUTICS | 4.96% |
| Alkermes Public Limited Company | 4.75% |
| ARGENX SE ADR | 4.43% |
| PRAXIS PRECISION MEDICINES | 4.30% |
| PTC THERAPEUTICS | 4.29% |
| DIANTHUS THERAPEUTICS | 3.98% |
Only in IHI
Show all 8 holdings
| ABBOTT LABORATORIES | 17.27% |
| INTUITIVE SURGICAL | 14.46% |
| MEDTRONIC PLC | 11.51% |
| IDEXX LABORATORIES | 5.48% |
| EDWARDS LIFESCIENCES | 4.96% |
| BECTON DICKINSON AND CO | 4.85% |
| GE HEALTHCARE TECHNOLOGIES | 4.63% |
| STRYKER | 4.59% |
Side by side
Open the table
| Fund | iShares Neuroscience and Healthcare ETF · Holds 67 stocks in therapeutics and medical devices, 5% of its weight in S&P 500 companies | iShares U.S. Medical Devices ETF · Holds 51 stocks in therapeutics and medical devices, 88% of its weight in S&P 500 companies |
| Issuer | iShares | iShares |
| Theme | Therapeutics and medical devices | Therapeutics and medical devices |
| In the S&P 500 | 5.3% | 88.5% |
| Active share vs the S&P 500 | 100.0% | 98.7% |
| In the Nasdaq-100 | 0.0% | 28.4% |
| Holdings | 67 | 51 |
| Top ten, share of the fund | 45.2% | 76.0% |
| Expense ratio | 0.47% | 0.37% |
| Fee for the differing part | 0.47% | 0.37% |
| Total return, 1 year | +19.8% | −7.4% |
| vs its benchmark | not measured | not measured |
| Below its high | −15.9% | −11.5% |
| Net assets, IBRN as of Nov 12, 2026 and IHI as of Nov 13, 2026 | $8.6m | $4.1bn |
As of Nov 13, 2026. Source: ETFIQ.
Window by window
Open the table
| 3 months | −12.6% | +4.2% |
|---|---|---|
| 6 months | −1.7% | +20.1% |
| 1 year | +19.8% | −7.4% |
| 3 years | +67.5% | +23.4% |
| Since launch (Not the same days: IBRN Aug 2022 · IHI May 2006) | +41.2% | +658.0% |
About IBRN
By weight, 5% of IBRN's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 100%. The top ten holdings are 45% of the fund across 67 positions, as published by its issuer for Nov 12, 2026.
More
Over the year to Nov 13, 2026 the fund returned +19.8% with distributions reinvested. It sits 15.9% below its all-time high of Aug 19, 2026.
About IHI
By weight, 88% of IHI's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 76% of the fund across 51 positions, as published by its issuer for Nov 12, 2026.
More
Over the year to Nov 13, 2026 the fund returned −7.4% with distributions reinvested. It sits 11.5% below its all-time high of Sep 8, 2021.
1% of the two portfolios are the same securities at the same weight.
Questions people ask
Do IBRN and IHI hold the same stocks?
By their latest filings, 1% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.
Other comparisons
Sources
More
Links are sources, not endorsements. A comparison is not a recommendation.
Copy and cite
Cite this pageCitation, APA and Markdown
ETFIQ, IBRN against IHI, data as of Nov 13, 2026. https://etfiq.com/compare/themes/ibrn-vs-ihi
ETFIQ. (Nov 13, 2026). IBRN against IHI. Retrieved from https://etfiq.com/compare/themes/ibrn-vs-ihi
[IBRN against IHI (ETFIQ, Nov 13, 2026)](https://etfiq.com/compare/themes/ibrn-vs-ihi)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.